147269-67-8Relevant articles and documents
Identification of Imidazo[1,2- b]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors
Liu, Chunjian,Lin, James,Moslin, Ryan,Tokarski, John S.,Muckelbauer, Jodi,Chang, ChiehYing,Tredup, Jeffrey,Xie, Dianlin,Park, Hyunsoo,Li, Peng,Wu, Dauh-Rurng,Strnad, Joann,Zupa-Fernandez, Adriana,Cheng, Lihong,Chaudhry, Charu,Chen, Jing,Chen, Cliff,Sun, Huadong,Elzinga, Paul,D'Arienzo, Celia,Gillooly, Kathleen,Taylor, Tracy L.,McIntyre, Kim W.,Salter-Cid, Luisa,Lombardo, Louis J.,Carter, Percy H.,Aranibar, Nelly,Burke, James R.,Weinstein, David S.
, p. 383 - 388 (2019)
In sharp contrast to a previously reported series of 6-anilino imidazopyridazine based Tyk2 JH2 ligands, 6-((2-oxo-N1-substituted-1,2-dihydropyridin-3-yl)amino)imidazo[1,2-b]pyridazine analogs were found to display dramatically improved metabolic stabilit
SYSTEMIC FORMULATION OF A PYRIDINONE DERIVATE FOR TG2-RELATED DISEASES
-
Paragraph 0666-0668, (2021/11/04)
The present invention relates to a formulation in particular an oral formulation for the prophylaxis and treatment of TG2-related disorders like fibrosis in particular diabetic nephropathy and/or diabetic associated non-alcoholic steatohepatitis (NASH) an
ARYL, HETEROARY, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS
-
Page/Page column 708, (2018/09/21)
Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.
